La vendita allo scoperto per Arbutus Biopharma dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Arbutus Biopharma. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Arbutus Biopharma (NASDAQ:ABUS) Azioni, Report sulle vendite allo scoperto

Arbutus Biopharma

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Arbutus Biopharma Corporation - Common Stock

Arbutus Biopharma Corp

News

General

FLUT

Boyd Gaming & FanDuel To Terminate Certain Existing Market-access Agreements Between Parties, Enter New Agreements; FanDuel To Also Continue To Operate Boyd's Retail Sportsbooks Outside Of Nevada Through Mid-2026

Offerings

IPSC

Century Therapeutics Files For Mixed Shelf Offering Of Up To $200M

RLMD

Relmada Therapeutics Terminates License Agreement With Dr. Charles E. Inturrisi & Dr. Paolo Manfredi; Ends Esmethadone Development Program

The board of trustees (the "Board") of&nbsp;NXG NextGen Infrastructure Income Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXG#NYSE">NXG</a>) (the "Fund") has approved the terms of the issuance of transferable rights ("Rights") to the holders of the Fund's common shares (the "Common Shareholders") of beneficial interest, par value $0.001 per share ("Common Shares"), as of the record date, entitling the holders of those Rights to subscribe for Common Shares (the "Offer"). The Board, based on the recommendations and presentations of the Fund's investment adviser, Cushing&#xAE; Asset Management, LP, doing business as NXG Investment Management (the "Investment Adviser"), and others, has determined that it is in the best interests of the Fund and the Common Shareholders to conduct the Offer and thereby to increase the assets of the Fund available for investment. In making this determination, the Board considered a number of factors, including potential benefits and costs. In particular, the Board considered the Investment Adviser's belief that the Offer would enable the Fund to take advantage of existing and future investment opportunities that may be or may become available, consistent with the Fund's investment objective to seek high total return with an emphasis on current income. The Offer also seeks to provide an opportunity to existing Common Shareholders to purchase Common Shares at a discount to market price (subject to a sales load).
The record date for the Offer is currently expected to be July 21, 2025 (the "Record Date"). The Fund will distribute to Common Shareholders on the Record Date ("Record Date Common Shareholders") one Right for each Common Share held on the Record Date. Common Shareholders will be entitled to purchase one new Common Share for every three Rights held (1 for 3); however, any Record Date Common Shareholder who owns fewer than three Common Shares as of the Record Date will be entitled to subscribe for one Common Share. Fractional Common Shares will not be issued.
The proposed subscription period will commence on the Record Date and is currently anticipated to expire on August 13, 2025, unless extended by the Fund (the "Expiration Date"). Rights may be exercised at any time during the subscription period. The Rights are transferable and are expected to be admitted for trading on the New York Stock Exchange LLC (the "NYSE") under the symbol "NXG RT" during the course of the Offer.
The subscription price per Common Share (the "Subscription Price") will be determined on the Expiration Date, and will be equal to 95% of the average of the last reported sales price of a Common Share of the Fund on the NYSE on the Expiration Date and each of the four (4) immediately preceding trading days (the "Formula Price"). If, however, the Formula Price is less than 90% of the Fund's net asset value per Common Share at the close of trading on the NYSE on the Expiration Date, the Subscription Price will be 90% of the Fund's net asset value per Common Share at the close of trading on the NYSE on that day. The estimated Subscription Price has not yet been determined by the Fund.

NXG NextGen Infrastructure Income Fund Announces 1-For-3 Transferable Rights Offering; Shareholders Can Subscribe At Discounted Price Starting July 21, 2025

Global

LEVI

During Conference Call, Levi Strauss CFO Reportedly Says Co Largely Sourcing From Bangladesh, Cambodia, Indonesia Along With About 1% From China, Mid-To-High Single Digits From Vietnam, Minimal From India

Morgan Stanley analyst Brian Nowak maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Overweight and raises the price target from $250 to $300.

Price Target

Analyst Ratings

AMZN

Morgan Stanley Maintains Overweight on Amazon.com, Raises Price Target to $300

Boyd Gaming To Sell FanDuel Interest For $1.755B; Transaction Is Expected To Close In Q3 Of 2025; Entered Into Deal To Sell Co's 5% Equity Interest In FanDuel To Flutter Entertainment Plc

<a href="https://www.justice.gov/opa/pr/statement-department-justice-antitrust-division-closing-its-investigation-merger-t-mobile#:~:text=%E2%80%9CAfter%20a%20thorough%20investigation%2C%20the,its%20proposed%20acquisition%20of%20UScellular" title="https://www.justice.gov/opa/pr/statement-department-justice-antitrust-division-closing-its-investigation-merger-t-mobile#:~:text=%E2%80%9CAfter%20a%20thorough%20investigation%2C%20the,its%20proposed%20acquisition%20of%20UScellular">https://www.justice.gov/opa/pr/statement-department-justice-antitrust-division-closing-its-investigation-merger-t-mobile#:~:text=%E2%80%9CAfter%20a%20thorough%20investigation%2C%20the,its%20proposed%20acquisition%20of%20UScellular</a>.

Legal

TMUS

Assistant Attorney General Gail Slater Of The Justice Department's Antitrust Division Issues Statement In Connection With The Closing Of The Department's Investigation Into The Proposed Acquisition Of UScellular By T-Mobile; Says Antitrust Division Determined Prudentially Not To Seek An Injunction To Prevent T-Mobile From Closing On Its Proposed Acquisition Of UScellular

Management

Federal Agricultural Mortgage CFO Aparna Ramesh To Resign

12-Month Parasiticide Treatment for Dogs Offers Unrivaled Duration of Flea and Tick Protection Compared to Existing Products
Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck &amp; Co., Inc., Rahway, N.J., USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), today announced the U.S. Food and Drug Administration (FDA) approval of BRAVECTO&#xAE; QUANTUM (fluralaner for extended-release injectable suspension) – a new, once-yearly1 injectable product to treat and protect dogs from fleas and ticks. The product is expected to be available at veterinary clinics and hospitals nationwide by August 2025.
BRAVECTO QUANTUM was first approved in Australia and New Zealand in 2023, followed by the European Union (EU) in 2024 and now the U.S. in 2025. In total, BRAVECTO QUANTUM is currently approved in more than 50 countries worldwide.

Biotech

Merck Animal Health Gains FDA Approval For BRAVECTO QUANTUM, First Once-Yearly Injectable Flea And Tick Treatment For Dogs, U.S. Launch Set For August 2025

Lake Street initiates coverage on Transcat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNS#NASDAQ">TRNS</a>) with a Buy rating and announces Price Target of $105.

Initiation

TRNS

Lake Street Initiates Coverage On Transcat with Buy Rating, Announces Price Target of $105

Trading Ideas

Morgan Stanley Raises Amazon.com 2026/2027 EPS Estimate By ~9%/+6% To $8/$9 On Lower Tariffs, Projects AWS Revenue Growth; Raises PT To $300 (+35% Upside) And $350 Bull Case (+60% Upside), Citing 4 Reasons for AWS Acceleration Ahead

CRGY

Crescent Energy Says For Three Months Ended June 30, 2025, Expects $37M From Hedge Positions

Axis Capital Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXS#NYSE">AXS</a>) has outperformed the market over the past 5 years by 5.3% on an annualized basis producing an average annual return of 19.74%. Currently, Axis Capital Holdings has a market capitalization of $7.65 billion. 
Buying $100 In AXS: If an investor had bought $100 of AXS stock 5 years ago, it would be worth $249.40 today based on a price of $97.25 for AXS at the time of writing.
<h3>Axis Capital Holdings's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752180318_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

The price of the XRP Token (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) from Ripple has soared in recent days on the heels of an announcement involving <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46323539/xrp-boosted-4-by-ripples-stablecoin-partnership-with-bny-mellon">the oldest bank </a>in the U.S.
Here's a look back at how much XRP has gained since a key moment in the cryptocurrency's history involving one of the most famous rappers around.
What Happened: The price of <a href="https://www.benzinga.com/money/ripple-xrp-price-prediction">XRP </a>is up 9.6% over <a href="https://www.benzinga.com/crypto/25/07/46337398/xrp-is-now-up-7-over-the-week-bolstered-by-ripples-partnership-with-alexander-hamilton-founded-bank-on-new-stablecoin-project">the past seven days,</a> outperforming other top 10 cryptocurrencies such as Bitcoin, Ethereum and Solana. XRP is currently the fourth-largest cryptocurrency by market capitalization, valued at $146 billion.
Interest in XRP could be up with Ripple announcing Wednesday that BNY Mellon, the oldest bank in the U.S., will serve as the primary custodian for reserves that back Ripple USD (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">RLUSD</a>), the company's stablecoin.
Along with the bank announcement, investors continue to be optimistic about XRP and other cryptocurrencies that could be approved ETFs in the future with 21Shares, WisdomTree and Grayscale all filing for spot XRP ETFs.
A battle between Ripple and SEC has also diminished in recent years, with Ripple recently withdrawing its appeal against the SEC. The current White House administration has withdrawn many lawsuits against cryptocurrency companies and paved the way for increased regulation and adoption.
While XRP is still trading below its 52-week high of $3.39 and its all-time high of $3.84 set back in 2018, the cryptocurrency is up significantly since a signficiant moment in its history.
Snoop Dogg,&nbsp;who has supported the cryptocurrency sector and non-fungible tokens, performed at a private invitation-only Consensus after-party from Ripple Labs on May 15, 2018.
The performance in New York saw several media outlets&nbsp;<a href="https://www.coindesk.com/markets/2018/05/19/at-ripples-snoop-dogg-party-a-search-for-xrp" target="_blank" rel="noreferrer noopener">cover&nbsp;</a>Snoop Dogg&#8217;s appearance and the fact that he did not talk about investing in cryptocurrency during his performance. Instead, the event was much like a celebration for the XRP community. Ripple previously said they did not pay Snoop Dogg with XRP tokens for his appearance.
While celebrities endorsing cryptocurrencies is nothing new, Snoop Dogg&#8217;s appearance may have marked an opportune moment to consider buying XRP — though the rapper offered no direct investment advice during the event.
Read Also: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46319635/xrp-ethereum-solana-and-one-surprise-crypto-not-bitcoin-are-bitwises-cleanest-plays">XRP, Ethereum, Solana And One Surprise Crypto (Not Bitcoin) Are Bitwise&#8217;s &#8216;Cleanest Plays&#8217;</a>
Investing $1,000 in XRP: Investors who learned about XRP for the first time with news of his appearance at the Ripple event, or thought that his appearance could signal optimism for the XRP token going forward, may have considered buying the cryptocurrency.
A $1,000 investment at the high price of $0.7523 on May 15, 2018, could have bought 1,329.26 XRP. The $1,000 investment would be worth $3,269.98 today based on a price of $2.46 at the time of writing, up 227%
XRP continues to be one of the most talked-about cryptocurrencies in recent months, and its continued strength and the potential approval of ETFs could lead to a higher price for the coin.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/25/06/45986682/if-you-invested-1000-in-bitcoin-when-nfl-star-saquon-barkley-took-endorsement-money-in-btc-heres-how-much-youd-have-today">If You Invested $1,000 In Bitcoin When NFL Star Saquon Barkley Took Endorsement Money In BTC, Here&#8217;s How Much You&#8217;d Have Today</a></li>
</ul>
This article was previously published by Benzinga and has been updated.
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Sector ETFs

Education

ETFs

$RLUSD

$XRP

If You Invested $1,000 In XRP Token When Snoop Dogg Performed At Ripple's 2018 Event, Here's How Much You'd Have Today

Loop Capital analyst Jeffrey Stevenson maintains Trex Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TREX#NYSE">TREX</a>) with a Hold and raises the price target from $62 to $66.

TREX

Loop Capital Maintains Hold on Trex Co, Raises Price Target to $66

Levi Strauss &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) reported second-quarter financial results after the market close on Thursday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/07/b46355222/levi-strauss-co-reports-second-quarter-2025-financial-results">of the report</a>.
Q2 Earnings: Levi Strauss reported second-quarter revenue of $1.45 billion, beating analyst <a href="http://benzinga.com/quote/LEVI/earnings">estimates</a> of $1.37 billion. The company reported second-quarter adjusted earnings of 22 cents per share, beating estimates of 13 cents per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Total revenue was up 6% on a year-over-year basis. Revenue was up 5% in the Americas, up 14% in Europe and flat in Asia. Direct-to-consumer revenue climbed 11% and wholesale revenue increased 3% year-over-year. 
Total inventories increased 15% on a dollar basis. The company ended the quarter with $654 million in cash and cash equivalents. 
&#8220;We delivered another strong quarter, reflecting broad-based strength across the board — clear evidence that our strategic agenda is gaining traction,&#8221; said Michelle Gass, president and CEO of Levi Strauss.
&#8220;We&#8217;re entering the second half of 2025 from a position of strength as our ambition to transform into a denim lifestyle brand and best-in-class DTC retailer becomes our reality.&#8221;
Outlook: Levi Strauss raised its full-year revenue growth guidance to a range of 1% to 2%. The company previously expected 1% to 2% declines in revenue for 2025. 
Levi also raised its full-year adjusted earnings guidance from a range of $1.20 to $1.25 per share to a new range of $1.25 to $1.30 per share, versus estimates of $1.23 per share.
LEVI Price Action: <a href="http://benzinga.com/quote/LEVI">Levi Strauss shares</a> were up 7.40% in after-hours, trading at $21.19 at the time of publication on Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/eurozone/25/07/46354754/greece-stock-market-2025-rally-grek-etf-banks">The Market Everyone Gave Up On Is Crushing Nasdaq 100 In 2025</a></li>
</ul>
Photo: Shutterstock.

Earnings

Guidance

After-Hours Center

Movers

Levi Strauss Shares Jump On Q2 Earnings, Revenue Beat, Raised Outlook

WIIM

AVAV

KTOS

ONDS

RCAT

UAVS

UMAC

Shares of drone stocks are trading higher after Secretary of Defense Pete Hegseth announced efforts to fast-track drone production.

Loop Capital analyst Anthony Chukumba maintains Dollar General (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) with a Hold and raises the price target from $110 to $120.

Loop Capital Maintains Hold on Dollar General, Raises Price Target to $120

<a href="https://x.com/SecDef/status/1943401411431026977" title="https://x.com/SecDef/status/1943401411431026977">https://x.com/SecDef/status/1943401411431026977</a>

Secretary of Defense Pete Hegseth Signs Memo, Announces Efforts To Boost Drone Industry

Press Releases

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Health Care

Arbutus Provides 2025 Corporate and Financial Update

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

Comments

Arbutus Biopharma

Vendite allo scoperto

Arbutus Biopharma (NASDAQ:ABUS) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO